KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2025)

CRISPR Therapeutics AG's Return on Capital Employed history spans 10 years, with the latest figure at 0.32% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 10.0% year-over-year to 0.32%; the TTM value through Dec 2025 reached 0.32%, down 10.0%, while the annual FY2025 figure was 0.32%, 10.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.32% at CRISPR Therapeutics AG, down from 0.28% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.19% in Q2 2021 and bottomed at 0.32% in Q4 2025.
  • The 5-year median for Return on Capital Employed is 0.22% (2021), against an average of 0.15%.
  • The largest annual shift saw Return on Capital Employed skyrocketed 37bps in 2021 before it tumbled -45bps in 2022.
  • A 5-year view of Return on Capital Employed shows it stood at 0.14% in 2021, then plummeted by -321bps to 0.31% in 2022, then surged by 65bps to 0.11% in 2023, then plummeted by -99bps to 0.22% in 2024, then tumbled by -46bps to 0.32% in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Return on Capital Employed are 0.32% (Q4 2025), 0.28% (Q3 2025), and 0.28% (Q2 2025).